lifestyle.longislandreport.org

Author: BriaCell Therapeutics Corp.

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

March 31, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

March 18, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

March 10, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

March 5, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

February 18, 2026
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

February 17, 2026
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

January 28, 2026
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

January 27, 2026